Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats

Clin Exp Nephrol. 2016 Dec;20(6):862-870. doi: 10.1007/s10157-016-1253-0. Epub 2016 Mar 7.

Abstract

Background: Proteinuria plays an essential role in the progression of tubulointerstitial damage, which causes end-stage renal disease. An increased load of fatty acids bound to albumin reabsorbed into proximal tubular epithelial cells (PTECs) contributes to tubulointerstitial damage. Fibrates, agonists of peroxisome proliferator-activated receptor α (PPARα), have renoprotective effects against proteinuria whereas the effects of these compounds on fatty acid metabolism in the kidney are still unknown. Therefore, the present study examined whether the renoprotective effects of clofibrate were associated with improvement of fatty acid metabolism in puromycin aminonucleoside (PAN)-induced nephrotic rats.

Methods: Rats were allocated to the control, PAN or clofibrate-treated PAN group. Biochemical parameters, renal injury and changes in fatty acid metabolism were studied on day14.

Results: PAN increased proteinuria, lipid accumulation in PTECs, excretions of N-acetyl-β-D-glucosaminidase (NAG) and 8-hydroxydeoxyguanosine (8OHdG) and the area of caspase 3-positive tubular cells. It decreased renal expressions of medium-chain acyl-CoA dehydrogenase (MCAD), cytochrome P450 (CYP)4A, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and estrogen-related receptor α (ERRα) without change of the expression of PPARα. Clofibrate reduced proteinuria, lipid accumulation, NAG excretion and the area of caspase 3-positive tubular cells. However, albumin excretion was not reduced and 8OHdG excretion was increased. Clofibrate minimized changes in MCAD, CYP4A, PGC-1α and ERRα expressions with increased PPARα, very long-chain acyl-CoA dehydrogenase (VLCAD) and long-chain acyl-CoA dehydrogenase (LCAD) expressions.

Conclusion: Clofibrate is protective against renal lipotoxicity in PAN nephrosis. This study indicates that clofibrate has renoprotective effects through maintaining fatty acid metabolism in the kidney of PAN-induced nephrotic rats.

Keywords: Clofibrate; Fatty acid metabolism; Lipotoxicity; Proteinuria.

MeSH terms

  • Animals
  • Clofibrate / pharmacology*
  • ERRalpha Estrogen-Related Receptor
  • Fatty Acids / metabolism*
  • Hypolipidemic Agents / pharmacology*
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney Glomerulus / drug effects
  • Kidney Glomerulus / pathology
  • Male
  • Nephrotic Syndrome / chemically induced
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / metabolism
  • PPAR alpha / agonists
  • Puromycin / toxicity*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Estrogen / analysis

Substances

  • Fatty Acids
  • Hypolipidemic Agents
  • PPAR alpha
  • Receptors, Estrogen
  • Puromycin
  • Clofibrate